AVITA Medical, Inc. (RCEL)
9.92
-0.14
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
9.92
0.00 (0.00%)
After-Hours: 20:00
AVITA Medical Shareholders Equity (Quarterly) : -27.84M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -27.84M |
| March 31, 2026 | -23.17M |
| December 31, 2025 | -16.65M |
| September 30, 2025 | -6.666M |
| June 30, 2025 | -12.89M |
| March 31, 2025 | -4.571M |
| December 31, 2024 | 4.499M |
| September 30, 2024 | 12.23M |
| June 30, 2024 | 23.92M |
| March 31, 2024 | 32.57M |
| December 31, 2023 | 49.06M |
| September 30, 2023 | 62.98M |
| Date | Value |
|---|---|
| June 30, 2023 | 68.65M |
| March 31, 2023 | 77.56M |
| December 31, 2022 | 84.74M |
| September 30, 2022 | 87.99M |
| June 30, 2022 | 92.56M |
| March 31, 2022 | 97.82M |
| June 30, 2021 | 115.66M |
| March 31, 2021 | 118.94M |
| December 31, 2020 | 59.60M |
| September 30, 2020 | 65.49M |
| June 30, 2020 | 72.40M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 143.54M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 47.78M |
| Total Liabilities (Quarterly) | 75.62M |
| Debt to Equity Ratio | -1.742 |
| Current Ratio | 0.4132 |
| Net Debt Paydown Yield | -0.69% |